4.2 Article

Epidemiological Trends of Hepatocellular Carcinoma in Austria

Journal

DIGESTIVE DISEASES
Volume 32, Issue 6, Pages 664-669

Publisher

KARGER
DOI: 10.1159/000367983

Keywords

Hepatocellular carcinoma; Epidemiology; Incidence; Mortality

Ask authors/readers for more resources

Background/Aims:The heterogeneous epidemiology of hepatocellular carcinoma (HCC) with the highest incidence rates in East Asia, sub-Saharan Africa and Melanesia results from variations in the main risk factors. We investigated epidemiological trends, including incidence and mortality, of patients diagnosed with HCC over a 20-year period in Austria. Methods: Data on age-adjusted incidence rates of HCC were obtained from the Austrian National Cancer Registry, which compiles nationwide data on all newly diagnosed cancers. Data on age-adjusted mortality were obtained from the national death registry (Statistics Austria). Results: Of 24,939 patients diagnosed with hepatobiliary tumors between 1990 and 2009, 8,561 subjects had HCC (m/f ratio 75/25%; mean age 69 years). Lymph node and distant metastases were present in 7.5 and 12.2%, respectively. The age-adjusted incidence rate was significantly higher in men than women (rn/f ratio 4.5/1) and markedly increased in men (4.68/5.10) but remained stable in women (1.18/1.11). Similarly, the age-adjusted mortality rate was significantly higher in men than women (m/f ratio 4.5/1), increased in men (4.02/4.98) and remained stable in women (0.92/1.0). The median overall survival was 4.5 months for men and 3.2 months for women with 1-/5-year survival rates of 33/11% and 28/10%, respectively. Conclusion: HCC is the most common hepatobiliary neoplasia in Austria and has a very poor prognosis. The age-adjusted incidence and mortality rates were higher in males, increased over time in men and remained stable in women. Extrahepatic metastases were rarely diagnosed and associated with dismal survival. (C) 2014 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy

Matthias Pinter, David J. Pinato, Pierluigi Ramadori, Mathias Heikenwalder

Summary: The past 10 years have brought about a revolution in our understanding of nonalcoholic fatty liver disease (NAFLD) and liver cancer. It has been discovered that various immune cells have a significant role in initiating and exacerbating nonalcoholic steatohepatitis (NASH), a newly defined autoaggressive disease. NASH is expected to become a leading cause of hepatocellular carcinoma (HCC) despite improved disease management. The effectiveness of immunotherapy in NASH-related HCC may be diminished compared to viral HCC, but further evidence is needed to support clinical translation of these findings.

CLINICAL CANCER RESEARCH (2023)

Review Gastroenterology & Hepatology

Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases

Frederik Nevens, Michael Trauner, Michael P. Manns

Summary: The discovery of nuclear receptors and transporters has contributed to the development of new drugs for the treatment of cholestatic liver diseases, particularly in the field of second-line therapies for PBC. These new drugs can target cholestasis, fibrogenesis, immune-mediated action, and symptom relief. Obeticholic acid is currently the only approved second-line therapy for PBC, while other drugs in late-stage clinical development include peroxisome proliferator-activated receptor agonists, norursodeoxycholic acid, and NADPH oxidase 1/4 inhibitors.

JOURNAL OF HEPATOLOGY (2023)

Article Hematology

Characterization of a prothrombotic phenotype using thrombin generation and thrombin activity in cirrhosis and portal hypertension

Oliver Koenigsbruegge, Bernhard Scheiner, Benedikt Simbrunner, Georg Semmler, Peter Quehenberger, Ingrid Pabinger-Fasching, Michael Trauner, Mattias Mandorfer, Ton Lisman, Cihan Ay, Thomas Reiberger

Summary: Patients with advanced chronic liver disease (ACLD) may develop a prothrombotic phenotype that seems to be more pronounced with more severe liver dysfunction. Routine coagulation assays cannot fully capture the imbalance of endogenous pro-and anti-coagulants. This study assessed thrombin generation (TGA) using two commercially available assays in ACLD patients.

THROMBOSIS RESEARCH (2023)

Article Medicine, General & Internal

Low mortality despite temporary liver dysfunction in severe courses of acute hepatitis E

David J. M. Bauer, Stephan Aberle, Anna Farthofer, David Chromy, Benedikt Simbrunner, Mattias Mandorfer, Ralf Schmidt, Michael Trauner, Robert Strassl, Florian Mayer, Heidemarie Holzmann, Thomas Reiberger

Summary: According to a study conducted at Vienna General Hospital from 2008 to 2018, Hepatitis E virus (HEV) infection can lead to severe viral hepatitis and liver failure. Despite an increase in HEV detection rates, the number of diagnosed HEV infections at Vienna General Hospital remained constant. While approximately half of the patients with severe acute HEV infection required hospitalization, admissions to the intensive care unit (ICU) and short-term mortality were low.

WIENER KLINISCHE WOCHENSCHRIFT (2023)

Article Gastroenterology & Hepatology

Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis

Georg Semmler, Bernhard Scheiner, Lorenz Balcar, Rafael Paternostro, Benedikt Simbrunner, Matthias Pinter, Michael Trauner, Marta Bofill Roig, Elias Laurin Meyer, Benedikt Silvester Hofer, Mattias Mandorfer, David James Pinato, Christian Zauner, Thomas Reiberger, Georg-Christian Funk

Summary: This study confirms the association between hypochloremia and prognosis in patients with cirrhosis, both in clinically stable patients and critically ill cases.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Article Gastroenterology & Hepatology

PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis

Michael Trauner, Chuhan Chung, Kate Sterling, Xiangyu Liu, Xiaomin Lu, Jun Xu, Clare Tempany-Afdhal, Zachary D. Goodman, Martti Faerkkilae, Atsushi Tanaka, Palak Trivedi, Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Robert P. Myers

Summary: This article presents the background of PSC and the design and implementation of the phase 3 PRIMIS trial, which aims to evaluate the efficacy and safety of cilofexor in noncirrhotic patients with large-duct PSC. The primary objective is to assess whether cilofexor reduces the risk of fibrosis progression compared with placebo.

BMC GASTROENTEROLOGY (2023)

Biographical-Item Gastroenterology & Hepatology

A tribute to Professor Peter Ferenci (1948-2023)

Daniel Shouval, Jay H. Hoofnagle, Michael Trauner

JOURNAL OF HEPATOLOGY (2023)

Correction Gastroenterology & Hepatology

Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease (vol 77, pg 918, 2022)

Katharina Staufer, Ursula Huber-Schoenauer, Georg Strebinger, Philipp Pimingstorfer, Silke Suesse, Thomas -Matthias Scherzer, Bernhard Paulweber, Peter Ferenci, Thomas Stimpfl, Michel Yegles, Christian Datz, Michael Trauner

JOURNAL OF HEPATOLOGY (2023)

Article Medicine, Research & Experimental

Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice

Jennifer K. Truong, Jianing Li, Qin Li, Kimberly Pachura, Anuradha Rao, Sanjeev Gumber, Claudia Daniela Fuchs, Andrew P. Feranchak, Saul J. Karpen, Michael Trauner, Paul A. Dawson

Summary: The choleretic properties of norUDCA are not mediated by bile acid transporters but by chloride channels in biliary epithelial cells. The results suggest a potential therapeutic synergy between norUDCA and ASBT inhibitors or bile acid sequestrants for cholestatic liver disease.

JCI INSIGHT (2023)

Article Gastroenterology & Hepatology

Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials

Claudia Angela Maria Fulgenzi, Bernhard Scheiner, James Korolewicz, Charalampos-Vlasios Stikas, Alessandra Gennari, Bruno Vincenzi, Mark R. Openshaw, Marianna Silletta, Matthias Pinter, Alessio Cortellini, Lorenza Scotti, Antonio D'Alessio, David J. Pinato

Summary: Direct comparisons across first-line regimens for advanced hepatocellular carcinoma are lacking. This network metanalysis compared first-line systemic treatments for hepatocellular carcinoma and found that ICI + anti-vascular endothelial growth factor combinations, as well as double ICIs, showed the greatest overall survival benefit. However, ICI + kinase inhibitor regimens were associated with greater progression-free survival benefit at the cost of higher toxicity rates.

JHEP REPORTS (2023)

Article Gastroenterology & Hepatology

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

David J. Pinato, Xiaoxue Li, Pallavi Mishra-Kalyani, Antonio D'Alessio, Claudia A. M. Fulgenzi, Bernhard Scheiner, Matthias Pinter, Guo Wei, Julie Schneider, Donna R. Rivera, Richard Pazdur, Marc R. Theoret, Sandra Casak, Steven Lemery, Lola Fashoyin-Aje, Alessio Cortellini, Lorraine Pelosof

Summary: This study analyzed the data of patients with hepatocellular carcinoma treated with immune checkpoint inhibitors (ICIs) and found that antibiotic exposure is associated with worse outcomes.

JHEP REPORTS (2023)

Article Biochemistry & Molecular Biology

Metabolic changes and propensity for inflammation, fibrosis, and cancer in livers of mice lacking lysosomal acid lipase

Ivan Bradic, Laura Liesinger, Katharina B. Kuentzel, Nemanja Vujic, Michael Trauner, Ruth Birner-Gruenberger, Dagmar Kratky

Summary: Lysosomal acid lipase (LAL) is responsible for degrading cholesteryl esters and triacylglycerols at acidic pH. Impaired LAL activity leads to LAL deficiency and non-alcoholic fatty liver disease (NAFLD). Comprehensive proteomic profiling of mouse livers with systemic or hepatocyte-specific loss of LAL revealed drastic proteome alterations in Lal-/- mice, including dysregulation of metabolism, inflammation, liver fibrosis, and cancer-related proteins. In contrast, hepLal-/- mice showed minor changes in the liver proteome, suggesting that loss of LAL solely in hepatocytes does not phenocopy the metabolic alterations observed in mice lacking LAL globally.

JOURNAL OF LIPID RESEARCH (2023)

Article Gastroenterology & Hepatology

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Bernhard Scheiner, Daniel Roessler, Samuel Phen, Mir Lim, Katharina Pomej, Tiziana Pressiani, Antonella Cammarota, Thorben W. Fruendt, Johann von Felden, Kornelius Schulze, Vera Himmelsbach, Fabian Finkelmeier, Ansgar Deibel, Alexander R. Siebenhuener, Kateryna Shmanko, Pompilia Radu, Birgit Schwacha-Eipper, Matthias P. Ebert, Andreas Teufel, Angela Djanani, Florian Hucke, Lorenz Balcar, Alexander B. Philipp, Claudia A. M. Fulgenzi, David J. Pinato, David Hsiehchen, Marino Venerito, Friedrich Sinner, Michael Trauner, Antonio D'Alessio, Claudia A. M. Fulgenzi, David J. Pinato, Markus Peck-Radosavljevic, Jean-Francois Dufour, Arndt Weinmann, Andreas E. Kremer, Amit G. Singal, Enrico N. De Toni, Lorenza Rimassa, Matthias Pinter

Summary: This study investigated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who had previously received ICI-based therapies. The results showed that ICI rechallenge was safe and resulted in a treatment benefit for some patients.

JHEP REPORTS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Diagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study

Sarah Poetter-Lang, Alina Messner, Nina Bastati, Kristina I. Ringe, Maxime Ronot, Sudhakar K. Venkatesh, Raphael Ambros, Antonia Kristic, Aida Korajac, Gregor Dovjak, Martin Zalaudek, Jacqueline. C. Hodge, Christoph Schramm, Emina Halilbasic, Michael Trauner, Ahmed Ba-Ssalamah

Summary: T1-MRC was found to be superior to T2-MRCP in diagnosing and locating strictures, as well as predicting prognosis in patients with primary sclerosing cholangitis.

EUROPEAN RADIOLOGY (2023)

Article Gastroenterology & Hepatology

GLP-2 Improves Hepatic Inflammation and Fibrosis in Mdr2-/- Mice Via Activation of NR4a1/Nur77 in Hepatic Stellate Cells and Intestinal FXR Signaling

Claudia D. Fuchs, Thierry Claudel, Veronika Mlitz, Alessandra Riva, Moritz Menz, Ksenia Brusilovskaya, Felix Haller, Maximilian Baumgartner, Philipp Koenigshofer, Lukas W. Unger, Wilhelm Sjoeland, Hubert Scharnagl, Tatjana Stojakovic, Georg Busslinger, Thomas Reiberger, Hanns-Ulrich Marschall, Michael Trauner

Summary: The GLP-2 analogue teduglutide has hepatoprotective and antifibrotic effects in a mouse model of sclerosing cholangitis. GLP-2 treatment decreases hepatic inflammation and fibrosis, and activates the intestinal FXR-FGF15/19 signaling axis, resulting in reduced expression of Cyp7a1 and increased expression of Cyp2c70 in the liver, contributing to its protective effects.

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY (2023)

No Data Available